SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-12-272627
Filing Date
2012-06-15
Accepted
2012-06-15 17:24:41
Documents
6
Period of Report
2012-06-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d368153d8k.htm 8-K 20168
2 UNDERWRITING AGREEMENT d368153dex11.htm EX-1.1 184509
3 OPINION OF GOODWIN PROCTER LLP d368153dex51.htm EX-5.1 6728
4 PRESS RELEASE d368153dex991.htm EX-99.1 10636
5 GRAPHIC g368153g77h04.jpg GRAPHIC 5230
6 GRAPHIC g368153g93e25.jpg GRAPHIC 2243
  Complete submission text file 0001193125-12-272627.txt   233894
Mailing Address 1140 ROUTE 22 EAST, SUITE 304 BRIDGEWATER NJ 08807
Business Address 1140 ROUTE 22 EAST, SUITE 304 BRIDGEWATER NJ 08807 (908) 704-1300
Aegerion Pharmaceuticals, Inc. (Filer) CIK: 0001338042 (see all company filings)

IRS No.: 202960116 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34921 | Film No.: 12910886
SIC: 2834 Pharmaceutical Preparations